.0801
Vaniqa and unwanted facial hair
Eflornithine HCl (Vaniqa - Vaniqa is pronounced 'Vanika')
13.9% cream is the first topical prescription treatment to
be approved by the US FDA for the reduction of unwanted
facial hair in women. It irreversibly inhibits ornithine
decarboxylase (ODC), an enzyme that catalyzes the
rate-limiting step for follicular polyamine synthesis, which
is necessary for hair growth. In clinical trials
eflornithine cream slowed the growth of unwanted facial hair
in up to 60% of women. Improvement occurs gradually over a
period of 4-8 weeks or longer. Most reported adverse
reactions consisted of minor skin irritation.

Buy
Vaniqa

Vaniqa is an enzyme inhibitor used topically to slow
the growth of unwanted facial hair in women. It does not
remove hair. Re-growth of unwanted hair can be dramatically
slowed by the use of Vaniqa and in some cases, hair becomes
so weak, it barely grows at all. The hairs that do grow
after continued use of Vaniqa become considerably weakened
which makes them finer and far less noticeable than coarse
thick or dark hair often associated with unwanted facial
hair in women.
Vaniqa is a cream that helps women to manage
unwanted facial hair. It is the first cream that is clinically proven to slow the
growth of unwanted facial hair in women. Vaniqa does not
remove hair . Applying this fragrance-free cream twice a
day, every day, does not replace your current method of
removal. Instead, Vaniqa complements it, by slowing hair
growth. You should continue to use your current method
of hair removal or treatment. Vaniqa is a prescription drug
for external use only.
Some medicines or medical conditions may
interact with this medicine. Inform your doctor or
pharmacist of all prescription and over-the-counter medicine
you are taking including any facial or skin creams. Also,
any other medical conditions such as broken skin, sores on
the face, allergies, or if you are pregnant or
breast-feeding should be indicated.
Vaniqa comes with a patient information
leaflet. Apply a thin layer of Vaniqa to the affected areas
of the face and under the chin, at least 5 minutes after
hair removal (e.g., plucking, shaving). Rub in thoroughly.
Do not wash the treated area for at least 4 hours. Wait at
least 8 hours between applications of this medicine.
Cosmetics or sunscreens may be applied after the Vaniqua
has dried. Store Vaniqa at room temperature (77 degrees F or
25 degrees C) in a tightly-closed container, away from heat
and light. Brief storage between 59 and 86 degrees F (15 and
30 degrees C) is permitted. Do not freeze. If you miss a
dose of this medicine, skip the missed dose and return to
your regular dosing schedule.
Vaniqa is not a depilatory agent. You will need to continue your
routine method of hair removal whilst using Vaniqa. You may
not see improvement for the first month of use.
Side effects of Vaniqa which may go away
during treatment include: stinging, burning, redness,
tingling, rash of the skin or hair follicle infection (folliculitis).
Vaniqa cream does not have contact sensitising, photocontact
allergic or phototoxic properties. It can cause irritation
under exaggerated conditions of use. Eflornithine HCl 13.9%
cream, therefore, has a favourable dermal safety profile
appropriate for a topical treatment to be applied routinely.0102
Related Medical Abstracts - Click on the paper title:-